Jennifer A. Fox - 12 Sep 2024 Form 3 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
Chief Business Officer and Chief Financial Officer. Exhibit List: Exhibit 24 - Power of Attorney
Signature
By: /s/ Chase Jayasekera, Attorney-in-Fact
Issuer symbol
ZBIO
Transactions as of
12 Sep 2024
Net transactions value
$0
Form type
3
Filing time
12 Sep 2024, 21:34:03 UTC
Previous filing
04 Sep 2024
Next filing
18 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZBIO Stock Option (Right to Buy) 12 Sep 2024 Common Stock 230,332 $11.90 Direct F1
holding ZBIO Stock Option (Right to Buy) 12 Sep 2024 Common Stock 233,211 $9.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the underlying shares of common stock on December 4, 2024, the first anniversary of the vesting commencement date, and as to the remaining shares in equal month installments over 36 months thereafter, subject to continued service.
F2 The option vests as to 25% of the underlying shares of common stock on May 7, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares in equal month installments over 36 months thereafter, subject to continued service.

Remarks:

Chief Business Officer and Chief Financial Officer. Exhibit List: Exhibit 24 - Power of Attorney